Global Lower Respiratory Tract Therapeutics Market Insights 2024, Forecast To 2033
8 Mar, 2024
Lower respiratory tract therapeutics market grew from $32.91 billion in 2023 to $35.8 billion in 2024, with an 8.8% CAGR driven by antibiotic discoveries. Expected expansion to $48.37 billion in 2028 (CAGR: 7.8%) is influenced by rising air pollution levels. Trends encompass precision medicine and biologic therapies.
Global Lower Respiratory Tract Therapeutics Market Key Driver
The lower respiratory tract therapeutics market is expanding with the rising prevalence of respiratory diseases, impacting 550 million adults globally in 2022. Early detection and diagnosis facilitated by lower respiratory tract therapeutics are essential for effective disease management and prevention of complications.
Get A Free Sample Of The Global Lower Respiratory Tract Therapeutics Market ReportGlobal Lower Respiratory Tract Therapeutics Market Segments
The lower respiratory tract therapeutics market covered in this report is segmented –
1) Disease Type:Asthma, Chronic obstructive pulmonary disease, Pneumonia, Tuberculosis, Bronchitis, Other Diseases
2) Drug Class:Antibiotics, Non-Steroidal Anti-Inflammatory Drug, Cough Suppressant, Nasal Decongestant, Other Drug Classes
3) Distribution Channel:Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The countries covered in the lower respiratory tract therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the lower respiratory tract therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lower respiratory tract therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Lower Respiratory Tract Therapeutics Industry Players
Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; GlaxoSmithKline plc.; Eli Lilly and Co Ltd.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Vertex Pharmaceuticals Incorporated; Grifols S.A.; Menarini Group; Chiesi Farmaceutici S.p.A.; Cipla Limited; BioMarin Pharmaceutical Inc.; Mundipharma International Limited; Orion Corporation; Sunovion Pharmaceuticals Inc.; Innoviva Inc.; Insmed Incorporated; Vectura Group plc; Kamada Ltd.; Theravance Biopharma Inc.; Verona Pharma plc; Circassia Pharmaceuticals plc
Get The Full Global Lower Respiratory Tract Therapeutics Market Report
Lower Respiratory Tract Therapeutics Market Overview
The lower respiratory tract refers to the portion of the respiratory system exchanging gases, where oxygen is taken in, and carbon dioxide is expelled. Lower respiratory tract therapeutics refers to the branch of medical science and clinical practice that focuses on diagnosing, treating, and managing diseases and disorders affecting the lower respiratory tract. These therapeutics improve the quality of life and overall health outcomes for individuals with lower respiratory tract disorders.